ATA157699A - Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate - Google Patents

Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate

Info

Publication number
ATA157699A
ATA157699A AT0157699A AT157699A ATA157699A AT A157699 A ATA157699 A AT A157699A AT 0157699 A AT0157699 A AT 0157699A AT 157699 A AT157699 A AT 157699A AT A157699 A ATA157699 A AT A157699A
Authority
AT
Austria
Prior art keywords
factor
antibody derivatives
activating antibodies
ixa activating
factor ixa
Prior art date
Application number
AT0157699A
Other languages
English (en)
Other versions
AT411997B (de
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3516408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATA157699(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Ag filed Critical Baxter Ag
Priority to AT0157699A priority Critical patent/AT411997B/de
Priority to ES00967666T priority patent/ES2288873T3/es
Priority to SK366-2002A priority patent/SK3662002A3/sk
Priority to CN00815678A priority patent/CN1390258A/zh
Priority to HU0203750A priority patent/HUP0203750A3/hu
Priority to CZ2002935A priority patent/CZ2002935A3/cs
Priority to RU2002109586/13A priority patent/RU2002109586A/ru
Priority to CA002384660A priority patent/CA2384660A1/en
Priority to JP2001523763A priority patent/JP4313531B2/ja
Priority to DE60035356T priority patent/DE60035356T2/de
Priority to PCT/EP2000/008936 priority patent/WO2001019992A2/en
Priority to PL00354976A priority patent/PL354976A1/xx
Priority to AU77759/00A priority patent/AU780775B2/en
Priority to EP00967666A priority patent/EP1220923B1/de
Priority to AT00967666T priority patent/ATE365799T1/de
Priority to US09/661,992 priority patent/US7033590B1/en
Publication of ATA157699A publication Critical patent/ATA157699A/de
Publication of AT411997B publication Critical patent/AT411997B/de
Application granted granted Critical
Priority to US11/093,103 priority patent/US7279161B2/en
Priority to JP2005380504A priority patent/JP2006111638A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT0157699A 1999-09-14 1999-09-14 Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate AT411997B (de)

Priority Applications (18)

Application Number Priority Date Filing Date Title
AT0157699A AT411997B (de) 1999-09-14 1999-09-14 Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
JP2001523763A JP4313531B2 (ja) 1999-09-14 2000-09-13 第ＩＸ因子／第ＩＸａ因子の抗体および抗体誘導体
PCT/EP2000/008936 WO2001019992A2 (en) 1999-09-14 2000-09-13 FACTOR IX/FACTOR IXa ANTIBODIES AND ANTIBODY DERIVATIV ES
CN00815678A CN1390258A (zh) 1999-09-14 2000-09-13 因子Ⅸ/因子lxa－抗体和抗体衍生物
HU0203750A HUP0203750A3 (en) 1999-09-14 2000-09-13 Factor ix/factor ixa antibodies and antibody derivatives
CZ2002935A CZ2002935A3 (cs) 1999-09-14 2000-09-13 Protilátky a deriváty protilátek k faktoru IX nebo faktoru IXa
RU2002109586/13A RU2002109586A (ru) 1999-09-14 2000-09-13 Антитела против фактора IX/фактора IXа и производные антител
CA002384660A CA2384660A1 (en) 1999-09-14 2000-09-13 Factor ix/factor ixa antibodies and antibody derivatives
ES00967666T ES2288873T3 (es) 1999-09-14 2000-09-13 Anticuerpos de activacion del factor ix/factor ixa.
DE60035356T DE60035356T2 (de) 1999-09-14 2000-09-13 Faktor ix/faktor ixa aktivierende antikörper
SK366-2002A SK3662002A3 (en) 1999-09-14 2000-09-13 Factor ix/factor ixa antibodies and antibody derivatives
PL00354976A PL354976A1 (en) 1999-09-14 2000-09-13 Factor ix/factor ixa antibodies and antibody derivatives
AU77759/00A AU780775B2 (en) 1999-09-14 2000-09-13 Factor IX/factor IXa antibodies and antibody derivatives
EP00967666A EP1220923B1 (de) 1999-09-14 2000-09-13 Faktor ix/faktor ixa aktivierende antikörper
AT00967666T ATE365799T1 (de) 1999-09-14 2000-09-13 Faktor ix/faktor ixa aktivierende antikörper
US09/661,992 US7033590B1 (en) 1999-09-14 2000-09-14 Factor IX/factor IXa activating antibodies and antibody derivatives
US11/093,103 US7279161B2 (en) 1999-09-14 2005-03-28 Factor IX/factor IXa activating antibodies and antibody derivatives
JP2005380504A JP2006111638A (ja) 1999-09-14 2005-12-28 第ＩＸ因子／第ＩＸａ因子の抗体および抗体誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0157699A AT411997B (de) 1999-09-14 1999-09-14 Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate

Publications (2)

Publication Number Publication Date
ATA157699A true ATA157699A (de) 2004-01-15
AT411997B AT411997B (de) 2004-08-26

Family

ID=3516408

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0157699A AT411997B (de) 1999-09-14 1999-09-14 Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
AT00967666T ATE365799T1 (de) 1999-09-14 2000-09-13 Faktor ix/faktor ixa aktivierende antikörper

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00967666T ATE365799T1 (de) 1999-09-14 2000-09-13 Faktor ix/faktor ixa aktivierende antikörper

Country Status (15)

Country Link
US (2) US7033590B1 (de)
EP (1) EP1220923B1 (de)
JP (2) JP4313531B2 (de)
CN (1) CN1390258A (de)
AT (2) AT411997B (de)
AU (1) AU780775B2 (de)
CA (1) CA2384660A1 (de)
CZ (1) CZ2002935A3 (de)
DE (1) DE60035356T2 (de)
ES (1) ES2288873T3 (de)
HU (1) HUP0203750A3 (de)
PL (1) PL354976A1 (de)
RU (1) RU2002109586A (de)
SK (1) SK3662002A3 (de)
WO (1) WO2001019992A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2003271186A1 (en) 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
EP2824183B1 (de) * 2005-04-08 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Verfahren zur Herstellung bispezifischer Antikörper
EP1760092A1 (de) * 2005-08-26 2007-03-07 Applied Research Systems ARS Holding N.V. System für Screening von Zellen mit hoher Expression von einem interessierenden Protein
EP4793360A2 (de) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blut-pharmazeutizität von antikörpern
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
MX2009006034A (es) * 2006-12-07 2009-10-12 Novartis Ag Anticuerpos antagonistas contra ephb3.
CA2680741A1 (en) 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
EP3127921A1 (de) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstition in cdr
KR102069498B1 (ko) * 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
AR071478A1 (es) 2008-04-17 2010-06-23 Baxter Healthcare Sa Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
JP2009292822A (ja) * 2009-07-23 2009-12-17 Chugai Pharmaceut Co Ltd 機能蛋白質を代替する二種特異性抗体
WO2011080322A1 (en) 2009-12-30 2011-07-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of prognosing the outcome of acquired hemophilia and of treatment of hemophilia
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
PL220297B1 (pl) * 2012-11-07 2015-10-30 Wrocławskie Ct Badań Eit & Spółka Z Ograniczoną Odpowiedzialności& Epitop i jego zastosowanie
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
US20190119385A1 (en) * 2015-03-27 2019-04-25 University Of Southern California Hla-g as a novel target for car t-cell immunotherapy
EP3273994B1 (de) 2015-03-27 2021-12-01 University of Southern California Car-t-zelltherapie gegen lhr zur behandlung von soliden tumoren
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
AU2017255077B2 (en) 2016-04-28 2024-05-16 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
SG11201809642TA (en) 2016-05-16 2018-11-29 Baxalta Inc Anti-factor ix padua antibodies
CA3027018A1 (en) 2016-07-29 2018-02-01 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
US11352438B2 (en) 2016-09-06 2022-06-07 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
CA3034105A1 (en) * 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
AU2017363309A1 (en) * 2016-11-23 2019-07-11 Bioverativ Therapeutics Inc. Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
KR102616666B1 (ko) 2016-12-23 2023-12-27 노파르티스 아게 인자 xi 항체 및 사용 방법
AU2018216008A1 (en) 2017-02-01 2019-08-01 Novo Nordisk A/S Procoagulant antibodies
JP7209298B2 (ja) 2017-03-31 2023-01-20 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CA3071236A1 (en) 2017-09-29 2019-04-04 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said moleculeas active ingredient
KR20260090008A (ko) 2017-11-01 2026-06-16 추가이 세이야쿠 가부시키가이샤 생물 활성이 저하된 항체 배리언트 및 아이소폼
EP3713965A1 (de) * 2017-11-22 2020-09-30 Novartis AG Reverse bindemittel für anti-faktor-xi/xia-antikörper und verwendungen davon
CN109836496A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向cd317的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CN109837303A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种敲除pd1的靶向cd317的嵌合抗原受体t细胞及其制备方法和应用
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
PE20211399A1 (es) 2018-08-01 2021-07-27 Novo Nordisk As Anticuerpos procoagulantes mejorados
US12703762B2 (en) 2018-12-18 2026-08-11 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
TWI772724B (zh) 2018-12-21 2022-08-01 英商克馬伯有限公司 具有共同輕鏈的FIXaxFX雙專一性抗體
WO2021152066A1 (en) 2020-01-30 2021-08-05 Novo Nordisk A/S Bispecific factor viii mimetic antibodies
CN115448985A (zh) * 2021-06-08 2022-12-09 上海循曜生物科技有限公司 新型抗栓抗体
CN118339188A (zh) 2021-09-21 2024-07-12 齐鲁普吉湾生物治疗公司 用于制备融合蛋白和双特异性抗体的异二聚体Fc
CN116333145B (zh) * 2023-04-14 2023-11-07 北京基科晟斯医药科技有限公司 结合活化凝血因子ix的抗体
CN116120447B (zh) * 2023-04-17 2024-09-06 北京纳百生物科技有限公司 IFN-γ蛋白单克隆抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0658168T3 (da) * 1992-08-27 2001-01-22 Sanquin Bloedvoorziening Antistoffer, som er specifikke for et hæmostatisk protein, anvendelse heraf til isolering af intakt protein, hæmostatiske p
DK128093D0 (da) * 1993-11-12 1993-11-12 Novo Nordisk As Hidtil ukendte forbindelser
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
EP1001991A4 (de) * 1997-07-03 2005-01-26 Smithkline Beecham Corp KRISTALLINE STRUKTUREN DER ANTI-FAKTOR IX Fab FRAGMENTE SOWIE VERWENDUNGSVERFAHREN ZUM PEPTIDOMIMETISCHEN DESIGN
ES2177316T3 (es) * 1998-08-28 2002-12-01 Genentech Inc Anticuerpos humanos antifacotores ix/ixa.
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity

Also Published As

Publication number Publication date
RU2002109586A (ru) 2004-03-10
CN1390258A (zh) 2003-01-08
US20050196397A1 (en) 2005-09-08
EP1220923A2 (de) 2002-07-10
CA2384660A1 (en) 2001-03-22
HUP0203750A2 (hu) 2003-02-28
DE60035356D1 (de) 2007-08-09
HUP0203750A3 (en) 2005-01-28
AU7775900A (en) 2001-04-17
PL354976A1 (en) 2004-03-22
US7033590B1 (en) 2006-04-25
JP4313531B2 (ja) 2009-08-12
US7279161B2 (en) 2007-10-09
AT411997B (de) 2004-08-26
WO2001019992A2 (en) 2001-03-22
WO2001019992A3 (en) 2001-09-27
ES2288873T3 (es) 2008-02-01
AU780775B2 (en) 2005-04-14
EP1220923B1 (de) 2007-06-27
JP2006111638A (ja) 2006-04-27
SK3662002A3 (en) 2002-07-02
JP2003509049A (ja) 2003-03-11
ATE365799T1 (de) 2007-07-15
CZ2002935A3 (cs) 2002-08-14
DE60035356T2 (de) 2008-02-14

Similar Documents

Publication Publication Date Title
DE60035356D1 (de) Faktor ix/faktor ixa aktivierende antikörper
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
TR200103576T2 (tr) Üre ikameli/katkılı imidazokinolinler.
ATE264863T1 (de) 28-epirapaloge
TR200103575T2 (tr) Sülfonamid ve sülfamid ikameli/katkılı imidazokinolinler
DK1189634T3 (da) Behandling af prostatacancer med anti-ErbB2-antistoffer
DE60035032D1 (de) Verwendung von pioglitazone zur verbesserung der ketose und der azidose
DE60023982D1 (de) System zur Behandlung von benigner Prostatahyperplasie
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
DE69901569D1 (de) Humane antikörper gegen faktor ix/ixa
ATE396197T1 (de) 17-alpha-substituierte-11-beta-substituierte-4- aryl und 21-substituierte 19-norpregnadienedione mit antigestagener aktivität
CY1106444T1 (el) 17b-νιτρο-11β-αρυλοστepοειδη και παραγωγα αυτων ως ορμονικοι αγωνιστες ή ανταγωνιστες
TR200102448T2 (tr) COPD tedavisi için kontrollu salma formülasyonu.
DE60233740D1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
ITRM990426A0 (it) Impiego di inibitori della sostanza p per il trattamento degli adenocarcinomi.
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
EP1274723A4 (de) AKTIVIERUNG VON PEPTID-PRO-ARZNEIMITTELN DURCH hK2
FI990781A0 (fi) Menetelmä lentotuhkan käsittelemiseksi
NO20022101D0 (no) Peptider for behandling av erektil dysfunksjon
RU99127550A (ru) Анксиолитическое средство
TR200103126T2 (tr) Yapısal titremenin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri

Legal Events

Date Code Title Description
MM01 Lapse because of not paying annual fees

Effective date: 20140115